An endothelin-transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 6, 1998, Pages 665-671

  Hutchinson, Ian V ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ENDOTHELIN; IMMUNOSTIMULATING AGENT; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

GENE ACTIVATION; GENE EXPRESSION REGULATION; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY GRAFT; NEPHROTOXICITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR SMOOTH MUSCLE;

CYCLOSPORINE; ENDOTHELINS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031774277     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199811000-00007     Document Type: Review

References (90)

1. Greenberg A, Egel JW, Thompson ME, Hardesty RL, Griffith BP, Bahnson HT, et al. Early and late forms of cyclosporine nephrotoxicity: studied in cardiac transplant recipients. Am J Kidney Dis 1987; 9:12-22.
2. Verani RR, Flechner SM, Van Buren CT, Kaha BD. Acute cellular rejection or cyclosporine A nephrotoxicity? A review of transplant renal biopsies. Am J Kidney Dis 1984; 9:185-191.
3. Myers BD, Ross J, Newton L, Luetscher J, Pertroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311:699-705.
4. Goldstein DJ, Zuechen N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantaion 1997; 63:664-668.
5. Miller RC, Pelton JT, Huggins JP. Endothelins - from receptors to medicine. Trends Pharmacol Sci 1993; 14:54-60.
6. Hunley TE, Valentina K. Endothelin in ischemic acute renal failure. Curr Opin Nephrol Hyertens 1997; 6:394-400.
7. Meyer-Lehnert H, Bokemeyer D, Friedrichs U, Backer A, Kramer HJ. Cellular mechanisms of cyclosporine A-associated side-effects: role of endothelin. Kidney Int 1997; 61 (suppl):S27-S31.
8. Medina J, Cordier A, Wolf A. Cyclosporine A-induced contraction of isolated rat aortic smooth muscle cells. Life Sci 1997; 61:327-332. This paper shows that the effects of cyclosporin on smooth muscle cells are mediated by endothelin.
9. Reimann D, Plug MJ, Gross P. Effects of cyclosporine A on endothelin-1 in cultured bovine renal artery endothelial cells (BRAEC) [abstract 430]. XXXVth Congress of the European Renal Association; 6-9 June; Rimini; 1998.
10. Marsen TA, Weber F, Baldamus CA. Regulated expression by cyclosporin A of a foreign fusion gene in human endothelial cells under the control of endothelin-1 gene promoter [abstract 30]. XXXVth Congress of the European Renal Association; 6-9 June; Rimini; 1998. This work was presented at a conference, and has yet to be published. It shows for the first time, however, a derepression of the endothelin gene by cyclosporin. If this observation can be substantiated it is an important step in our understanding of cyclosporin nephrotoxicity.
11. Klahr S, Morrissey J. Angiotensin II and gene expression in the kidney. Am J Kidney Dis 1998; 31:171-176.
12. Ruiz-Ortega M, Egido J. Antiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997; 52:1497-1510.
13. Sharma M, Sharma R, Greene AS, McCarthy ET, Savin VJ. Documentation of angiotensin II receptors in glomerular epithelial cells. Am J Physiol 1998; 274:F623-F627.
14. 2+-influx and store-release [abstract K507]. XXXVth Congress of the European Renal Association; 6-9 June; Rimini; 1998.
15. Marsen TA, Simonson MS, Dunn MN. Roles of calcium and kinases in regulation of thrombin-stimulated preproendothelin-1 transcription. Am J Physiol 1996; 271:H1918-H1925.
16. 2+ channels. Kidney Int 1996; 49:868-879.
17. Asiedu CK, Scotto L, Assoian RK, Ehrlich M. Binding of AP-1/CREB protiens and of MDBP to contiguous sites downstream of the human TGF-beta 1 gene. Biochem Biophys Acta 1994; 1219:55-63.
18. Hahn AW, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR. Stimlation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul 1990; 1:649-659.
19. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ III, Kim SJ. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol 1994; 8:595-602.
20. Kim SJ, Park K, Rudkin BB, Dey BR, Sporn MB, Roberts AB. Nerve growth factor induces transcription of transforming growth factor-beta 1 through a specific promoter element in PC12 cells. J Biol Chem 1994; 269:3739-3744.
21. Coligan JE, Kehrl JH, Fauci AS. Selective autoregulation of endothelins in primary astrocyte cultures: endothelin receptor-mediated potentiation of endothelin-1 secretion. New Biol 1991; 3:135-141.
22. Kojima M, Ohata K, Yasue H. Structural organization and chromosomal assignment of the swine endothelin-1 gene. J Vet Med Sci 1997; 59:431-435.
23. Lee ME, Bloch KD, Clifford JA, Quertermous T. Functional analysis of the endothelin-1 gene promoter. Evidence for an endothelial cell-specific cis-acting sequence. J Biol Chem 1990; 265:10446-10450.
24. Kawana M, Lee ME, Quertermous EE, Quertermous T. Cooperative interaction of GATA-2 and AP1 regulates transcription of the endothelin-1 gene. Mol Cell Biol 1995; 15:4225-4231.
25. Kudoh SA, Komuro I, Mizuno T, Yamazaki T, Zou Y, Shiogima I, et al. Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res 1997; 80:139-146.
26. Lee ME, Dhadly MS, Temizer DH, Clifford JA, Yoshizumi M, Quertermous T. Regulation of endothelin-1 gene expression by Fox and Jun. J Biol Chem 1991; 266:19034-19039.
27. Maass A, Grohe C, Kubisch C, Wollnik B, Vetter H, Neyses L. Hormonal induction of an immediate - early gene response in myogenic cell lines - a paradigm for heart growth. Eur Heart J 1995; 16:12-14.
28. Neyses L, Nouskas J, Luyken J, Fronhoffs S, Oberdorf S, Pfeifer U, et al. Induction of immediate - early genes by angiotensin II and endothelin-1 in adult rat cardiomyocytes. J Hypertens 1993; 11:927-934.
29. Hofer G, Grimmer C, Sukhatme VP, Sterzel RB, Rupprecht HD. Transcription factor EgM regulates glomerular mesangial cell proliferation. J Biol Chem 1996; 271:28306-28310.
30. Takeshita A, Chen Y, Watanabe A, Kitano S, Hanazawa S. TGF-beta induces expression of monocyte chemoattractant JE/monocyte chemoattractant protein 1 via transcriptional factor Ap-1 induced by protein kinase in osteoblastic cells. J Immunol 1995; 155:419-226.
31. Chung KY, Agarwal A, Ditto J, Mauviel A. An AP-1 binding sequence is essential for regulation of the human alpha 2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem 1996; 271:3272-3278.
32. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997; 15:519-526. An interesting overview is presented.
33. Tang W, Yang L, Yang YC, Leng SX, Elias JA. Transforming growth factor-beta stimulates interleukin-11 transcription via complex activating protein-1-dependent pathways. J Biol Chem 1998; 273:5506-5513. Interleukin-11 inhibits cytokine production by inflammatory macrophages and stimulates B cell growth. This may contribute to the anti-inflammatory effects of TGF-β.
34. Uria JA, Jimenez MG, Balbin M, Freije JMP, Lopez-Otin C. Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J Biol Chem 1998; 273:9769-9777.
35. Khanna A, Li B, Stenzel KH, Suthanthiran M. Regulation of new DNA synthesis in mammalian cells by cyclosporine. Demonstration of transforming growth factor beta-dependent mechanism of inhibition of cell growth. Transplantation 1994; 57:577-582.
36. Ahuja SS, Shrivastav S, Danielpour D, Balow J, Boumpas DT. Regulation of transforming growth factor-β1 and its receptor by cyclosporine in human T lymphocytes. Transplantaion 1995; 60:718-723.
37. Prashar Y, Khanna A, Sehajpal P, Sharma VK, Suthanthiran M. Stimulation of transforming growth factor-β1 transcription by cyclosporine. FEBS Lett 1995; 358:109-112.
38. Wolf G, Zahner G, Ziyadeh FN, Stahl RA. Cyclosporin A induces transcription of transforming growth factor beta in a cultured murine proximal tubular cell line. Exp Nephrol 1996; 4:304-308.
39. Shehata M, Cope GH, Johnson TM, Raftry AT, Nahas AM. Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Int 1995; 48:1487-1496.
40. Khanna A, Kapur S, Sharma V, Li B. Suthanthiran M. In vivo hyperexpres-sion of transforming growth factor-beta 1 in mice: stimulation by cyclosporine. Transplantaion 1997; 63:1037-1039. This paper demonstrates that cyclosporin treatment in mice increases TGF-β1 production, as it does in humans.
41. El Gamel A, Awad M, Yonan N, Keevil B, Egan J, Campbell C, et al. Does cyclosporin promote the secretion of transforming growth factor-beta 1 following pulmonary transplantation? Transplant Proc 1998; 30:1525-1527. This paper shows a relationship between cyclosporin trough levels and the circulating level of TGF-β in lung transplant patients.
42. •], and shows that even a brief exposure to clinically relevant doses of cyclosporin induces a four to fortyfold increase in TGF-β levels in man.
43. Hutchinson IV. The mode of action of Prograf (tacrolimus) and its significance for long-term graft survival. New Horizons in Kid Transplant 1997; 1:22-26.
44. Khanna A, Cairns V, Hosenpud J. TGF-β mimics and anti-TGF-β reverses the anti-proliferative effects of cyclosporine in vivo [abstract 529]. Transplantation 1998; 65:5135. The study shows that the elevation of TGF-β levels by cyclosporin probably contributes to its immunosuppressive effects.
45. Liu A, Ballermann BJ. TGF-beta type II receptor in rat renal vascular development: localization of juxtaglomerular cells. Kidney Int 1998; 53:716-725.
46. Yang YL, Guh JY, Yang ML, Lai YH, Tsai JH, Hung WC, et al. Interactions between high glucose and TGF-beta in cell cycle protein regulations in MDCK cells. J Am Soc Nephrol 1998; 9:182-193.
47. Negoescu A, Lafeuillade B, Pellerin S, Chambaz EM, Feige JJ. Transforming growth factors beta stimulate both thrombospomdin-1 and CISP/thrombospondin-2 synthesis by bovine adrenocortical cells. Exp Cell Res 1995, 217:404-409.
48. Van de Ven WJ, Voorberg J, Fontijn R, Pannekoek H, van den Ouweland AM, van Duijinhoven HL, et al. Furin is a subtilisin-like proprotein processing enzyme in higher eukaroytes. Mol Biol Rep 1990; 14:265-275.
49. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R. Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 1995; 270:10618-10624.
50. Hugo C, Shankland SJ, Pichler RH, Couser WG, Johnson RJ. Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int 1998; 53:302-311.
51. Derynk R. Tranforming growth factor-beta. In: The cytokine handbook. 2nd ed. Thomson A (editor). London, San Diego, New York, Boston, Sydney, Tokyo, Toronto: Harcourt Brace and Company; 1994. pp. 319-342.
52. Kulkarni AB, Karlsson S. Inflammation and TGF beta 1: lessons from the TGF beta 1 null mouse. Res Immunol 1997; 147:453-456. A good review of the role played by TGF-β in regulating inflammation.
53. Kitamura M. TGF-β1 as an endogenous defender against macrophage-triggered stomelysin gene expression in the glomerulus. J Immunol 1998; 160:5163-5168.
54. Kitamura M, Fine LG. Evidence for TGF-beta-mediated 'defense' of the glomerulus: a blackguard molecule rehabilitated? Exp Nephrol 1998; 6:1-6.
55. Vodovotz Y, Kopp JB, Takeguchi H, Shrivastav S, Coffin D, Lucia MS, et al. Increased mortality, blunted production of nitric oxide, and incrased production of TNF-alpha in endotoxemic TGF-beta 1 transgenic mice. J Leukoc Biol 1998; 63:31-39.
56. Antonipillai I, Le TH, Soceneantu L, Horton R. Transforming growth factor-beta is a renin secretagogue at picomolar concentrations. Am J Physiol 1993; 265:F537-F541.
57. Swain SL, Huston G, Tonkonogy S, Weinberg A. Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol 1991; 147:2991-3000.
58. Gerritsma JA, van Kooten C, Gerritsen AF, van Es LA, Daha MR. Transforming growth factor-beta 1 regulates chemokine and complement production by human proximal tubular epithelial cells. Kidney Int 1998; 53:609-616. These experiments show an upregulation of interleukin-8 production by TGF-β, an effect likely to have a consequence in increasing graft infiltration. Tacrolimus is said to suppress interleukin-8 synthesis in psoriatic patients.
59. 1 on albumin permeability of rat glomeruli in vitro [abstract 130]. Transplantation 1998; 65:S35 Not all the effects of TGF-β are chronic, as is shown in this study. Very rapid changes in glomerular function were induced by TGF-β.
60. Cuhaci B, Bloom R, Laskow D, Kumar A, Alidoost M, Grotkowski C, et al. The rate of decline in renal function in chronic allogratt rejection (fibrosis) can be predicted by intratubular levels of transforming growth factor beta (TGF-β) [abstract 350]. Transplantation 1998; 65:391.
61. + CTL. J Immunol 1997; 159:3748-3756.
62. Fowler BZ, Rostapshova EA, Drachenberg Cl, Bartlett ST, Hadley GA. Expression of the epithelial cell-specific integrin, CD103, by CD8 cells that infiltrate rejecting allografts in a non-vascularized mouse kidney transplant model [abstract A-233]. 24th Annual Scientific Meeting of the American Society of Transplant Surgeons; 13-15 May 1998. This line of work by Hadley and his colleagues is interesting and possibly very important because it pinpoints a new mechanism of tubulitis and cell-mediated destruction of tubules. This mechanism is brought about by TGF-β, and it remains to be seen whether this effect is greater in cyclosporin-treated patients than in those on other agents.
63. Clouthier DE, Comerford SA, Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome inn PEPCK-TGF-beta 1 transgenic mice. J Clin Invest 1997; 100:2697-2713.
64. Peters H, Noble NA, Border WA. Transforming growth factor-β in human glomerular injury. Curr Opin Nephrol Hypertens 1997; 6:389-393. A good review of recent work.
65. Khanna AK, Cairns VR, Becker CG, Hosenpud JD. TGF-β: a link between immunosuppression, nephrotoxicity, and CsA. Transplant Proc 1998; 30:944-945.
66. Khanna A, Cairns V, Hosenpud J. TGF-β mimics and anti-TGF-β reverses the anti-proliferative effects of cyclosporine in vivo [abstract 306]. Transplantation 1998; 65:S79.
67. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997; 64:1829-1837.
68. Rao P, Sun H, Snyder J, Fung JJ, Starzl TE. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. Transplant Proc 1991; 23:2873-2874.
69. 1 expression by FK-506 (tacrolimus). J Heart Lung Transplant 1997.
70. Bicknell GR, Williams S, Furness PN, Nicholson ML. A comparison of extracellular matrix gene expression in renal transplant biopsies from patients randomised to cyclosporin or FK506. Transplant Proc 1998; in press. This study of gene expression in glomeruli plucked from transplant biopsies of cyclosporin or tacrolimus-treated patients reveals significant differences in the net activation of matrix accumulation. The fibrogenic effect of cyclosporin was greater than that of tacrolimus.
71. Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997; 17:1148-1156.
72. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50:1110-1117.
73. 1) expression in immortalized rat proximal tubules cells (IRPTC) [abstract 396]. Transplantation 1998; 65:3101.
74. Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62:311-316.
75. Wei CM, Song H, Fink J, Klassen D, Papadimitriou J, DrachenbergC, et al. Decreased expression of transforming growth factor-beta (TGF-β) in biopsies with chronic allograft nephropathy after one year of 50% cyclosporine level reduction and mycophenolate addition [abstract 228]. Transplantation 1998; 65:359.
76. Carmellini M, Frosini F, Filipponi F, Boggi U, Mosca F. The effect of cilastatin on cyclosporine-induced acute nephrotoxicity in kidney transplant recipients. Transplantaion 1997; 64:164-166.
77. Yoo KH, Wolstenholme JT, Chevalier RL. Angiotensin-converting enzyme inhibition decreases growth factor expression in the neonatal rat kidney. Pediatr Res 1997; 42:588-592.
78. Klahr S, Morrissey JJ. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int 1997; 63 (suppl):S111-S114.
79. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen UL, Jerums G, Cooper ME. Expression of transforming growth factor-beta 1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998; 47:414-422.
80. Szabo A, Schleimer K, Müller V, Hamar P, Viklicky O, Heemann U. ACE inhibition reduces growth factor gene production in chronic renal allograft rejection [abstract X388]. XXXVth Congress of the European Renal Association; 6-9 June; Rimini; 1998.
81. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TFG-beta 1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52:660-673.
82. Junaid A, Hostetter TH, Rosenberg ME. Interaction of antiotensin II and TGF-beta 1 in the rat remnant kidney. J Am Soc Nephrol 1997; 8:1732-1738.
83. Zoja C, Abbate M, Coma D, Capitanio M, Donadelli R, Bruzzi I, et al. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis 1998; 31:453-463.
84. Ding G, van Goor H, Ricardo SD, Ortowski JM, Diamond JR. Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int 1997; 51:147-154.
85. Ferri C, Bellini C, Desideri G, De Mattia G, Santucci A. Endogenous insulin modulates circulating endothelin-1 concentrations in humans. Diabetes Care 1996; 19:504-506.
86. Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, et al. Advanced glycation end product-induced activation of NF-kappa B is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997; 46:1481-1490.
87. Nath KA, Grande J, Croatt A, Haugen J, Kim Y, Rosenberg ME. Redox regulation of renal DNA synthesis, transforming growth factor-beta 1 and collagen gene expression. Kidney Int 1998; 53:367-381.
88. Kassab S, Miller MT, Novak J, Reckelhoff J, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl Saft-sensitive rats. Hypertension 1998; 31:397-402.
89. Rabelink TJ, Luscher TF. Endothelin antagonists on the clinical horizon in nephrology. Curr Opin Nephrol Hypertens 1996; 5:389-392.
90. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci 1998; 19:5-8. An update on endothelin is presented.